Lung Cancer Risk Prediction Nomogram in Nonsmoking Chinese Women: Retrospective Cross-sectional Cohort Study
JMIR Public Health and Surveillance · 2023-01-06 · 9 · e41640
DOI: 10.2196/41640 ↗At a glance
Kohortenstudie in JMIR Public Health and Surveillance, published online on 2023-01-06. Written by Lanwei Guo and 10 co-authors. Institution: Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Labor…. Major MEDLINE topics: Nomograms, Lung Neoplasms. Cited 10 times so far (Crossref); 58 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
It is believed that smoking is not the cause of approximately 53% of lung cancers diagnosed in women globally.
Objective
The study aimed to develop and validate a simple and noninvasive model that could assess and stratify lung cancer risk in nonsmoking Chinese women.
Methods
Based on the population-based Cancer Screening Program in Urban China, this retrospective, cross-sectional cohort study was carried out with a vast population base and an immense number of participants. The training set and the validation set were both constructed using a random distribution of the data. Following the identification of associated risk factors by multivariable Cox regression analysis, a predictive nomogram was developed. Discrimination (area under the curve) and calibration were further performed to assess the validation of risk prediction nomogram in the training set, which was then validated in the validation set.
Results
In sum, 151,834 individuals signed up to take part in the survey. Both the training set (n=75,917) and the validation set (n=75,917) were comprised of randomly selected participants. Potential predictors for lung cancer included age, history of chronic respiratory disease, first-degree family history of lung cancer, menopause, and history of benign breast disease. We displayed 1-year, 3-year, and 5-year lung cancer risk–predicting nomograms using these 5 factors. In the training set, the 1-year, 3-year, and 5-year lung cancer risk areas under the curve were 0.762, 0.718, and 0.703, respectively. In the validation set, the model showed a moderate predictive discrimination.
Conclusions
We designed and validated a simple and noninvasive lung cancer risk model for nonsmoking women. This model can be applied to identify and triage people at high risk for developing lung cancers among nonsmoking women.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, The Affiliated Cancer Hospital of Zhengzho…
- Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
ORCID profiles: Lanwei Guo, Qingcheng Meng, Liyang Zheng, Qiong Chen, Yin Liu, Huifang Xu, Ruihua Kang, Luyao Zhang, Shuzheng Liu, Xibin Sun, Shaokai Zhang
Cite
APA
Guo, L., Meng, Q., Zheng, L., Chen, Q., Liu, Y., Xu, H., Kang, R., Zhang, L., Liu, S., Sun, X., & Zhang, S. (2023). Lung Cancer Risk Prediction Nomogram in Nonsmoking Chinese Women: Retrospective Cross-sectional Cohort Study. JMIR Public Health and Surveillance, 9, e41640. https://doi.org/10.2196/41640
Vancouver
Guo L, Meng Q, Zheng L, Chen Q, Liu Y, Xu H, et al. Lung Cancer Risk Prediction Nomogram in Nonsmoking Chinese Women: Retrospective Cross-sectional Cohort Study. JMIR Public Health and Surveillance. 2023;9:e41640. doi:10.2196/41640
BibTeX
@article{Guo2023,
author = {Guo, Lanwei and Meng, Qingcheng and Zheng, Liyang and Chen, Qiong and Liu, Yin and Xu, Huifang and Kang, Ruihua and Zhang, Luyao and Liu, Shuzheng and Sun, Xibin and Zhang, Shaokai},
title = {Lung Cancer Risk Prediction Nomogram in Nonsmoking Chinese Women: Retrospective Cross-sectional Cohort Study},
journal = {JMIR Public Health and Surveillance},
year = {2023},
volume = {9},
pages = {e41640},
doi = {10.2196/41640}
}
EUVIMED